Expert Interview
Digging into Alnylam's recent topline vutrisiran data from the HELIOS-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM)
Ticker(s): ALNYInstitution: Stanford
- Cardiologist and Instructor at Stanford University School of Medicine.
- Manages patients at the amyloid center at Stanford and directs the amyloid clinic at the Palo Alto VA.
- Research focuses on Investigating the molecular mechanisms behind genetic risk factors for human cardiovascular disease focusing on amyloidosis, cardio-oncology, and atherosclerotic diseases.
Roughly how many patients do you treat with ATTR-CM?
Added By: sara_adminWhat are your thoughts on the recent data from the HELIOS-B Phase 3 study of vutrisiran?
Added By: sara_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of vutrisiran, what would it be and why?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
